ARCHIVES

FDA Approves Gemzar For Ovarian Cancer, Contradicting ODAC Recommendation; Continues Agency Trend to Recognize Progression-Free Survival As An Endpoint.

This article is from The Cancer Letter archive.

Vol. 32 No. 28 | July 21, 2006

Download PDF Visit The Full Archive

Related Articles

“Soft Soap” Comprehensive Center Review Still Stung Some; NSAB Left With Perplexing Situations

May 26, 1978

Guest Editorial: Andrew Vickers on PSA Skepticism, Rational and Irrational

October 10, 2014

CIRC Attempting To Write Guidelines For Budget Review Of Cooperative Groups

March 6, 1981

Virus Working Group Suggests 14 Projects As Suitable For New Contract Proposals

March 1, 1974

An Early Look At How NCI Plans To Spend Its Money In 1980

July 7, 1978

Senate “Pleased” About Reductions In Incidence And Mortality

October 8, 1999